Mechanism of Action Angiogenic Modulation and Growth Factor Upregulation The mechanism of BPC-157 is centered on its ability to trigger the Early Growth Response 1 (EGR-1) gene and subsequently upregulate the Vascular Endothelial Growth Factor (VEGF)
For subcutaneous injections, a standard insulin syringe is typically used
BPC-157 Molecular Formula: CHNO CAS Number: 137525-51-0 Amino Acid Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Synonyms: Body Protection Compound-157 Molar Mass: 1,419.5355 g/mol TB-500 Molecular Formula: C38H68N10O14 (varies depending on manufacturing) CAS Number: 885340-08-9 (free base) Amino Acid Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Glu-Glu-Ala-Glu-Asp-Leu-Asn-Glu-Glu-Glu-Lys-Glu-Ala-Gly-Glu-Ser Synonyms: Thymosin Beta-4 Fragment (TB-500) Molar Mass: 889.02 (may vary) Wolverine Storage Recommendations Before reconstitution: Store lyophilized vials in a cool, dry place at 28C (refrigerated) and away from light
Epithalon commonly stacks with MOTS-c (mitochondrial), NAD+ (cellular coenzyme), or CJC-1295/Ipamorelin (growth peptides) for comprehensive longevity protocols
Injection Site Reactions: Mild redness, swelling, or discomfort at injection sites (typically resolves quickly)
Monitoring approach: Establish clear metrics (visual field, OCT, visual acuity), measure every 3-6 months, continue peptides if stable or improving, consider break if stable 12+ months on treatment, resume immediately if decline detected during break, accept ongoing use if clearly beneficial and well-tolerated
